이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Role of NSI in Differentiating Between Mild Traumatic Brain Injury And Behavioral Health Conditions

2017년 5월 12일 업데이트: VA Eastern Colorado Health Care System

Differentiating Between Mild Traumatic Brain Injury And Behavioral Health Conditions: The Role of The Neurobehavioral Symptom Inventory

The purpose of this study is to examine differences in post-concussive (PC) symptom endorsement among four groups of Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans: those with a history of target, service-related, mild traumatic brain injury (mTBI) and co-occurring posttraumatic stress disorder (PTSD) (Group 1); those with a history of target, service-related, mTBI only (Group 2); those with PTSD only (Group 3); and those with no history of target, service-related, mTBI or PTSD (Group 4) by examining scores on the Neurobehavioral Symptom Inventory (NSI). Support for this study is provided by previous research highlighting the complex relationship between mTBI, PTSD and subsequent PC symptom endorsement (Brenner et al. 2010; Terrio et al, 2009).

HYPOTHESES ARE AS FOLLOWS:

  1. Individuals with a history of target, service-related, mTBI only (Group 2) and individuals with PTSD only (Group 3) each will report significantly more PC symptoms, as measured by NSI total scores, when compared to those with no history of service-related mTBI or PTSD (Group 4).
  2. Individuals with co-occurring target, service-related, mTBI history and PTSD (Group 1) will report significantly more PC symptoms, as measured by total NSI scores, than either those with target, service-related, mTBI only (Group 2) or those with PTSD only (Group 3).

연구 개요

상세 설명

Archival data will be collected from all OEF/OIF Veterans who were seen in the VA ECHCS TBI Clinic by Nancy Cutter, M.D. and her team between January 1, 2009 and December 31, 2010. Electronic Medical Record (EMR) progress note titles "OEF/OIF TBI 2nd Level Evaluation Consult Report" and "TBI Consult Report" will be used to identify potential subjects.

Power is based on the primary hypothesis that those with PTSD only (Group 3) and those with target, service-related mTBI only (Group 2) will have significantly more PC symptom reporting than those with no history of target, service-related mTBI or PTSD (Group 4). Belanger et al. (2010) reported a standard deviation of 15.3 on the NSI total score in a sample of 134 mTBI subjects. Assuming variability similar to the Belanger study, a significance level of 0.025 to correct for the two comparisons and 80% power, 180 subjects per group will detect a clinically significant difference of 5 points. For simplicity, this was calculated using a two-sided, two-sample t-test. Given that we are modeling all four groups together, pooled standard error estimates will be used, which will result in slightly higher power.

All analyses will assume a two-sided test of hypothesis with an overall significance level of 0.05, unless otherwise noted, and will be performed in either Statistical Analysis Software (SAS) v9.2 or above (SAS Institute, Inc., Cary, NC).

Demographic characteristics will be reported as means and standard deviations; medians and ranges; and proportions, as appropriate. Likewise, characteristics will be compared between the four aforementioned subject groups using Analysis of Variance (ANOVA), chi-square tests and/or nonparametric tests as appropriate.

Hypothesis 1: An ANOVA with reference cell coding will be utilized to model NSI total score as a function of the four groups (Group 1: Individuals with co-occurring target, service-related, mTBI and PTSD; Group 2: those with target, service-related, mTBI only; Group 3: those with PTSD only; and Group 4: those with no history of target, service-related, mTBI or PTSD). Potential confounders will then be assessed individually by adding them to the model with the groups. If any of the group parameter estimates changes by more than 10% with the inclusion of the potential confounder, the variable will be utilized in the final model. Once the final model is determined, a contrast will be set up within the model to test (1) PTSD only vs. Neither and (2) target, service-related, mTBI only vs. Neither, a Bonferroni correction will be employed such that the significance level will be adjusted to 0.025 for these two primary tests. Estimated mean differences will be reported with 95% CIs. Potential confounding variables to be considered are: age; gender; total number of deployments; time since last deployment; time since earliest documented mTBI; time since target, service-related, mTBI; and total number of mTBIs.

Hypothesis 2: Within the same final model above, a contrast will be used to test (1) those with co-occurring target, service-related, mTBI and PTSD vs. PTSD only and (2) those with co-occurring target, service-related, mTBI and PTSD vs. target, service-related, mTBI only.

연구 유형

관찰

등록 (실제)

887

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Colorado
      • Denver, Colorado, 미국, 80220
        • VA Eastern Colorado Health Care System

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Archival data will be collected from all OEF/OIF Veterans who were seen in the VA ECHCS TBI Clinic by Nancy Cutter, M.D. and her team between January 1, 2009 and December 31, 2010. Electronic Medical Record (EMR) progress note titles "OEF/OIF TBI 2nd Level Evaluation Consult Report" and "TBI Consult Report" will be used to identify potential subjects.

설명

Inclusion criteria for all groups includes:

  • Veteran must be between the ages of 18 to 60
  • Veteran must have at least one OEF/OIF deployment
  • Veteran must have received an OEF/OIF TBI 2nd Level Evaluation though the VA ECHCS TBI Clinic

Specific inclusion/exclusion criteria for each group are as follows:

Inclusion Criteria:

Group 1: (Both) Co-Occurring PTSD and target, service-related, mTBI

PTSD:

  • Clinician confirmed PTSD diagnosis and continuous documentation of symptoms related to PTSD diagnosis within 1 year prior to being seen in the TBI Clinic, or
  • Clinician confirmed PTSD diagnosis within 1 year prior to being seen in the TBI Clinic, or
  • Clinician confirmed PTSD diagnosis within 60 days after being seen in TBI Clinic
  • Target, service-related, mTBI
  • Veterans with clinician confirmed target, service-related, mTBI per OEF/OIF TBI 2nd Level Evaluation Consult Report note in EMR

Group 2: (mTBI only) History of target, service-related, mTBI but with no diagnosis of PTSD

  • PTSD:
  • Veterans with no history of clinician confirmed PTSD diagnosis, or
  • Veterans with previous clinician confirmed PTSD diagnosis , but without continuous documentation of PTSD symptoms within 1 year prior to being seen in the TBI clinic
  • Target, service-related, mTBI
  • Veterans with clinician confirmed target, service-related, mTBI per OEF/OIF TBI 2nd Level Evaluation Consult Report note in EMR

Group 3: (PTSD only) No history of target, service-related, mTBI but with a diagnosis of PTSD

  • PTSD:
  • Clinician confirmed PTSD diagnosis and continuous documentation of symptoms related to PTSD diagnosis within 1 year prior to being seen in the TBI Clinic, or
  • Clinician confirmed PTSD diagnosis within 1 year prior to being seen in the TBI Clinic, or
  • Clinician confirmed PTSD diagnosis within 60 days of being seen in TBI Clinic
  • TBI:
  • Veterans with no history of clinician confirmed diagnosis of target, service-related, mTBI
  • Veterans with clinician confirmed mTBI prior to service and without continuous documentation of related symptoms within 1 year of being seen in the TBI Clinic

Group 4: (Neither) No history of target, service-related, mTBI and no diagnosis of PTSD

  • PTSD:
  • Veterans with no history of clinician confirmed PTSD diagnosis, or
  • Veterans with previous clinician confirmed PTSD diagnosis , but without continuous documentation of PTSD symptoms within 1 year of being seen in the TBI clinic
  • TBI:
  • Veterans with no clinician confirmed diagnosis of target, service-related, mTBI

Exclusion Criteria:

  • Those not meeting inclusion criteria as listed above, and
  • Veterans with any history of clinician confirmed moderate or severe TBI, and
  • Veterans with no NSI in TBI Consult Report note in EMR
  • Veterans with documentation of any neurological event or disorder other than mTBI
  • Veterans with positive brain imaging

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: 보병대
  • 시간 관점: 회고전

코호트 및 개입

그룹/코호트
개입 / 치료
OEF/OIF Veterans
Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
This retrospective data analysis will rely on data obtained from chart review.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Neurobehavioral Symptom Inventory
기간: 1 day (NSI was administered 1 time during clinical visit and documented in EMR as described below)

The Neurobehavioral Symptom Inventory (NSI; Cicerone & Kalmar, 1995)is a 22-item self-report measure of PC symptoms recommended for use among military personnel by the Department of Defense (DoD). Subject responses to all 22 items will be extracted from each subject's TBI Consult Report note provided in her/his Electronic Medical Record (EMR).

Estimated time to collect all data from this retrospective chart review is 1 year.

1 day (NSI was administered 1 time during clinical visit and documented in EMR as described below)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Gina Signoracci, Ph.D., VA Eastern Colorado Health Care System

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2011년 3월 1일

기본 완료 (실제)

2015년 5월 1일

연구 완료 (실제)

2015년 5월 1일

연구 등록 날짜

최초 제출

2011년 12월 9일

QC 기준을 충족하는 최초 제출

2011년 12월 30일

처음 게시됨 (추정)

2012년 1월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 5월 15일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 5월 12일

마지막으로 확인됨

2012년 12월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다